Objective  To explore the clinical effect of Liuwei Dihuang decoction on thrombocytopenia (HIT) of liver and kidney yin deficiency in hemodialysis patients.

Methods  84 hemodialysis patients with liver and kidney yin deficiency HIT were randomly divided into observation group and control group, with 42 cases in each group. The control group was treated with conventional western medicine, while the observation group was treated with Liuwei Dihuang decoction on the basis of the control group. The scores of liver and kidney yin deficiency syndrome before and after treatment and the curative effect of traditional Chinese medicine syndrome were compared between the two groups, and the platelet count (Plt), P-selectin level, HIT antibody before and after treatment, the platelet recovery time and clinical efficacy and adverse reactions of the two groups were also compared.

Results  After 1 month of treatment, the scores of liver and kidney yin deficiency syndrome in the two groups were both lower than those before treatment (P<0.05), which in the observation group was lower than that of the control group (P<0.05). The total effective rate of traditional Chinese medicine syndromes in the observation group (97.62%) was higher than that in the control group (P<0.05). After 14 d of treatment, the Plt of the two groups were both higher than those before treatment, while the levels of P-selectin and the positive rate of HIT antibody of the two groups were lower than those before treatment(P<0.05), and the Plt in the observation group was higher than that of the control group, the levels of P-selectin and the positive rate of HIT antibody in the observation group were lower than those in the control group (P<0.05). The platelet recovery time in the observation group was shorter than that in the control group (P<0.05), the total effective rate of clinical treatment in the observation group (95.24%) was higher than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05).

Conclusion  On the basis of conventional western medicine treatment, the addition of Liuwei Dihuang decoction to treat HIT of liver and kidney yin deficiency in hemodialysis patients can improve the clinical efficacy, reduce the clinical symptoms of patients, improve the level of Plt, shorten the recovery time of platelet, and reduce the level of P-selectin and the positive rate of HIT antibody, with good safety, which is worthy of clinical promotion.

1.Claudel SE, Miles LA, Murea M. Anticoagulation in hemodialysis: a narrative review[J]. Semin Dial, 2021, 34(2): 103-115. DOI: 10.1111/sdi.12932．

2.Toyoda Y，Tateno K，Takeda Y，et al．Significance of mild thrombocytopenia in maintenance hemodialysis patients; a retrospective cohort study[J]. Platelets, 2022, 33(5): 735-742. DOI: 10.1080/09537104.2021.1983531．

3.李红, 卫飞燕, 邓春青, 等. 小剂量阿加曲班补救治疗人工肝治疗中出现的肝素介导性血小板减少症1例[J]. 中华肝脏病杂志, 2021, 29(12): 1198-1200. [Li H, Wei FY, Deng CQ, et al. Low-dose argatroban emerging salvage therapies for heparin-induced thrombocytopenia during artificial liver treatment:a case report[J]. Chinese Journal of Hepatology, 2021, 29(12): 1198-1200.] DOI: 10.3760/cma.j.cn501113-20201215-00655．

4.高丽霓, 孔晓琳, 刘冠男, 等. PCI术后肝素诱导的血小板减少症Ⅰ型与Ⅱ型的中医证候特征及证候差异性研究[J]. 现代中西医结合杂志, 2020, 29(13): 1383-1386,1395. [Gao LN, Kong XL, Liu GN, et al. Study on syndrome characteristics and differences of heparin-induced thrombocytopenia type Ⅰ and type Ⅱ after PCI surgery[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2020, 29(13): 1383-1386,1395] DOI: 10.3969/j.issn.1008-8849.2020.13.004.

5.杨娟娟, 吕忠美, 王姝琴. 六味地黄丸联合辛伐他汀对肾阴亏损型糖尿病肾病病人炎症免疫指标和肾纤维化的影响[J]．中西医结合心脑血管病杂志, 2022, 20(12): 2241-2244. [Yang JJ, Lyu ZM, Wang SQ. Effects of Liuwei Dihuang pill and simvastatin on inflammatory immune indexes and renal fibrosis in diabetes nephropathy patients with kidney yin deficiency[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2022, 20(12): 2241-2244.] DOI: 10.12102/j.issn.1672-1349.2022.12.025．

6.闫盈滨, 闫中亮, 吕中阳. 六味地黄丸对慢性再生障碍性贫血的疗效及对EPO、SCF细胞因子活性的影响[J]. 中医药信息, 2010, 27(4): 102-104. [Yan YB, Yan ZL, Lyu ZY. Effect of Liuwei Dihuang pill on chronic aplastic anemia and influence on the activity of EPO and SCF cytokines[J]. Information on Traditional Chinese Medicine, 2010, 27(4): 102-104.] DOI: 10.3969/j.issn.1002-2406.2010.04.049．

7.曹红春. 加味六味地黄汤治疗肿瘤化疗所致的血小板减少症的临床疗效观察[D]. 成都: 成都中医药大学, 2016.

8.吴茂林, 周红, 邱萌, 等. 自拟振元汤治疗化疗后血小板减少的临床疗效评价[J]. 西部中医药, 2012, 25(2): 75-77. [Wu ML, Zhou H, Qiu M, et al. Evaluation of self-made ZhenYuanTang in treating thrombopenia after chemotherapy[J]. Western Journal of Traditional Chinese Medicine, 2012, 25(2): 75-77.] DOI: 10.3969/j.issn.1004-6852.2012.02.030．

9.董芬, 李超, 彭晓霞, 等. 临床研究中样本含量计算的意义、计算方法及注意事项[J]. 中国卒中杂志, 2009, 4(10): 854-859. [Dong F, Li C, Peng XX, et al. The significance, calculation methods and attention about sample size in the clinical research[J]. Chinese Journal of Stroke, 2009, 4(10): 854-859.] DOI: 10.3969/j.issn.1673-5765.2009.10.020．

10.郭俊勇, 温涛, 单泓, 等. 藻酸双酯钠联合利伐沙班治疗下肢深静脉栓塞并发肝素诱导血小板减少症临床研究[J]. 安徽医药, 2018, 22(10): 1979-1982. [Guo JY, Wen T, Shan H, et al. Clinical observation of alginic sodium diester combined with rivaroxaban in treatment of lower limb deep vein thrombus complicated with heparin-induced thrombocytopenia[J]. Anhui Medical and Pharmaceutical Journal, 2018, 22(10): 1979-1982.] DOI: 10.3969/j.issn.1009-6469.2018.10.036．

11.韩雅玲, 史旭波, 郭静萱, 主编. 抗栓与溶栓治疗[M]. 北京: 人民军医出版社, 2014: 56-57.

12.郑筱萸, 主编．中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 253-258.

13.吴承玉, 主编. 中医诊断学, 第2版[M]. 上海: 上海科学技术出版社, 2011: 191-192.

14.沈悌, 赵永强, 主编. 血液病诊断及疗效标准, 第4版[M]. 北京: 科学出版社, 2018: 145-149.

15.Levin SR, Farber A, Siracuse JJ. Preservation of heparin-bonded prosthetic graft for hemodialysis in the setting of early heparin-induced thrombocytopenia[J]. Ann Vasc Surg, 2020, 65(5): 282. DOI: 10.1016/j.avsg.2019.12.017.

16.Lee HW, An JN, Lee HS, et al. Neutrophil extracellular traps and heparin-induced antibodies contribute to vascular access thrombosis in hemodialysis patients[J]. Kidney Res Clin Pract, 2021, 40(4): 712-723. DOI: 10.23876/j.krcp.21.080.

17.晋辉, 邱翠婷, 刘静, 等. 比较阿加曲班和比伐卢定在高出血风险且肝素诱导的血小板减少症-IgG抗体阳性的ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗中的抗凝疗效[J]. 中国循环杂志, 2019, 34(6): 545-551. [Jin H, Qiu CT, Liu J, et al. Anticoagulation efficacy comparison between argatroban and bivalirudin during emergency percutaneous coronary intervention in acute ST-segment elevation myocardial infarction patients with high bleeding risk and positive HIT-IgG antibody[J]. Chinese Circulation Journal, 2019, 34(6): 545-551.] DOI: 10.3969/j.issn.1000-3614.2019.06.005.

18.陈月红, 胡莉文. 从肝论治原发免疫性血小板减少症急性期[J]. 中国中医急症, 2020, 29(11): 2047-2049. [Chen YH, Hu LW. Treatment of acute stage of primary immune thrombocytopenia from liver[J]. Journal of Emergency in Traditional Chinese Medicine, 2020, 29(11): 2047-2049.] DOI: 10.3969/j.issn.1004-745X.2020.11.048.

19.苏艳, 王艳芬, 董丽萍. 知柏地黄汤对阴虚火旺型儿童性早熟的疗效探究[J]. 中国妇幼保健, 2022, 37(17): 3169-3172. [Su Y, Wang YF, Dong LP. Effect of Zhibai Dihuang decoction on precocious puberty in children with yin deficiency and fire hyperactivity[J]. Maternal and Child Health Care of China, 2022, 37(17): 3169-3172.] DOI: 10.19829/j.zgfybj.issn.1001-4411.2022.17.019.

20.李亚, 潘志强, 钱宏梁, 等. 六味地黄汤和桂附地黄汤对小剂量氢化可的松减停给药后致小鼠药源性虚证的调节作用[J]. 中国实验方剂学杂志, 2020, 26(11): 63-70. [Li Y, Pan ZQ, Qian HL, et al. Regulatory effect of Liuwei Dihuangtang and Guifu Dihuangtang on low-dose hydrocortisone reduction and discontinuance in mice with drug-induced deficiency syndrome[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020, 26(11): 63-70.] DOI: 10.13422/j.cnki.syfjx.20200902.

21.王洋洋, 冯卫生, 王秋红, 等. 基于"运脾生血"理论的熟地黄补血作用代谢组学研究[J]. 中国中药杂志, 2022, 47(13): 3562-3568. [Wang YY, Feng WS, Wang QH, et al. Metabolomic profiling reveals blood-tonifying effect of Rehmanniae Radix Praeparata based on theory of activating spleen and generating blood[J]. China Journal of Chinese Materia Medica, 2022, 47(13): 3562-3568.] DOI: 10.19540/j.cnki.cjcmm.202220220322.401.

22.宋佳琪, 付正丰, 陈浩, 等. 人参-山茱萸化学成分分析及其对环磷酰胺所致小鼠骨髓抑制的影响[J]. 中国野生植物资源, 2022, 41(9): 29-35. [Song JQ, Fu ZF, Chen H, et al. Analysis of chemical constituents of Panax ginseng C.A.Mey-Cornus officinalis Sieb.et Zucc and the effects on myelosuppression induced by cyclophosphamide in mice[J]. Chinese Wild Plant Resources, 2022, 41(9): 29-35.] DOI: 10.3969/j.issn.1006-9690.2022.09.006.

23.朱云飞. 山药中增加血小板数量成分的提取及口含片的研制[D]. 西安: 陕西科技大学, 2012.

24.王卓亚, 杨发满, 周红梅, 等. 慢性高原病患者血浆组织因子微粒和P-选择素与凝血功能异常的关系研究[J]. 中国全科医学, 2020, 23(27): 3416-3421. [Wang ZY, Yang FM, Zhou HM, et al. Relationship of abnormal coagulation with plasma TF-MPs and P-selectin in patients with chronic mountain sickness[J]. Chinese General Practice, 2020, 23(27): 3416-3421.] DOI: 10.12114/j.issn.1007-9572.2020.00.238．

25.Zhou Y, Wang S, Feng W, et al. Structural characterization and immunomodulatory activities of two polysaccharides from Rehmanniae Radix Praeparata[J]. Int J Biol Macromol, 2021, 186: 385-395. DOI: 10.1016/j.ijbiomac.2021.06.100.

26.Zhang L, Li DC, Liu LF. Paeonol: pharmacological effects and mechanisms of action[J]. Int Immunopharmacol, 2019, 72: 413-421. DOI: 10.1016/j.intimp.2019.04.033．

27.Chao CL, Huang HW, Su MH, et al. The lanostane triterpenoids in Poria cocos play beneficial roles in immunoregulatory activity[J]. Life (Basel), 2021, 11(2): 111. DOI: 10.3390/life11020111．